Compounds > guatteguamerine
Page last updated: 2024-12-08

guatteguamerine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

guatteguamerine: a neuroprotective agent with antioxidant properties; isolated from bark of Guatteria gaumer; structure given in first source; RN given refers to (R-(R*,R*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GuatteriagenusA plant genus of the family ANNONACEAE. Members contain asarone, isoguattouregidine (an isoquinoline alkaloid), norlaureline, puterine, noraporphine alkaloids.[MeSH]AnnonaceaeThe custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH]

Cross-References

ID SourceID
PubMed CID362563
CHEBI ID6642
SCHEMBL ID2823145
MeSH IDM0147930

Synonyms (14)

Synonym
NSC626646 ,
7-isoquinolinol,2,3,4-tetrahydro-1-[[4-[2-hydroxy-5-[(1,2,3,4-tetra hydro-7-hydroxy-6-methoxy-2-methyl-1-isoquinolinyl) methyl]phenoxy]phenyl]methyl-6-methoxy-2-methyl-, [s-(r*,s*)]-
nsc-626646
1-[[4-[2-hydroxy-5-[(7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenoxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol
7-isoquinolinol, 1,2,3,4-tetrahydro-1-[[4-[2-hydroxy-5-[(1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]phenyl]methyl-6-methoxy-2-methyl-, [s-(r*,s*)]-
magnoline
6859-66-1
C06515
guatteguamerine
FT-0601522
CHEBI:6642
SCHEMBL2823145
Q27107286
magnoline (stereochemistry undefined)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
bisbenzylisoquinoline alkaloidA type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.4110aromatic ether;
nitrile;
polyether;
tertiary amino compound
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		2.0510inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
glycocholic acid
Glycocholic Acid: The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed.. glycocholic acid : A bile acid glycine conjugate having cholic acid as the bile acid component.. glycocholate : A cholanic acid conjugate anion that is the conjugate base of glycocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		2.4110bile acid glycine conjugatehuman metabolite
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.0510dialdehydebiomarker
magnocurarine
magnocurarine: RN given refers to (R)-isomer		2.3110isoquinolines
chondocurine (1beta)-(+-)-isomer
curine: structure in first source		2.4110aromatic ether
armepavine
armepavine: reticuline-like; RN given refers to cpd without isomeric designation		2.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.1710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1710
Alloxan Diabetes
[description not available]		02.0810
Diabetic Glomerulosclerosis
[description not available]		02.0810
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.0810